The DOI matches its Crossref record; 48 of the 50 references it cites were found in a registry or an index.
Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
Open accessPublished version of a preprint
Abstract
Purpose: Deregulated Myc drives an oncogenic metabolic state, including pseudohypoxic glycolysis, adapted for the constitutive production of biomolecular precursors to feed rapid tumor cell growth. In glioblastoma, Myc facilitates renewal of the tumor-initiating cell reservoir contributing to tumor maintenance. We investigated whether targeting the Myc-driven metabolic state could be a selectively toxic therapeutic strategy for glioblastoma. Experimental Design: The glycolytic dependency of Myc-driven glioblastoma was tested using 13C metabolic flux analysis, glucose-limiting culture assays, and glycolysis inhibitors, including inhibitors of the NAD+ salvage enzyme nicotinamide phosphoribosyl-transferase (NAMPT), in MYC and MYCN shRNA knockdown and lentivirus overexpression systems and in patient-derived glioblastoma tumorspheres with and without MYC/MYCN amplification. The in vivo efficacy of glycolyic inhibition was tested using NAMPT inhibitors in MYCN-amplified patient-derived glioblastoma orthotopic xenograft mouse models. Results: Enforced Myc overexpression increased glucose flux and expression of glycolytic enzymes in glioblastoma cells. Myc and N-Myc knockdown and Myc overexpression systems demonstrated that Myc activity determined sensitivity and resistance to inhibition of glycolysis. Small-molecule inhibitors of glycolysis, particularly NAMPT inhibitors, were selectively toxic to MYC/MYCN–amplified patient-derived glioblastoma tumorspheres. NAMPT inhibitors were potently cytotoxic, inducing apoptosis and significantly extended the survival of mice bearing MYCN-amplified patient-derived glioblastoma orthotopic xenografts. Conclusions: Myc activation in glioblastoma generates a dependency on glycolysis and an addiction to metabolites required for glycolysis. Glycolytic inhibition via NAMPT inhibition represents a novel metabolically targeted therapeutic strategy for MYC or MYCN-amplified glioblastoma and potentially other cancers genetically driven by Myc. Clin Cancer Res; 22(17); 4452–65. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
NAMPT inhibitors may be more effective in MYC-amplified glioblastoma or when combined with other drugs that deplete NAD+ pools.
“For example, NAMPT inhibitors may be more effective in contexts of MYC-amplified glioblastoma (Tateishi et al., 2016) or when used in combination with other drugs known to deplete NAD+ pools (Bajrami et al., 2012; Chan et al., 2014).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Tateishi et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,888
Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
Glioma Groups Based on 1p/19q, IDH , and TERT Promoter Mutations in Tumors
Eckel‐Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,981
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Mertz, J. A., Conery, A. R., Bryant, B. M., Sandy, P., Balasubramanian, S., Mele, D. A., Bergeron, L., & Sims, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108190108 · Cited by 1,145
Sugimoto, M., Wong, D. T., Hirayama, A., Soga, T., & Tomita, M. (2009) · Metabolomics · doi:10.1007/s11306-009-0178-y · Cited by 1,011
Quantitative Metabolome Analysis Using Capillary Electrophoresis Mass Spectrometry
Soga, T., Ohashi, Y., Ueno, Y., Naraoka, H., Tomita, M., & Nishioka, T. (2003) · Journal of Proteome Research · doi:10.1021/pr034020m · Cited by 981
Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
Yun, J., Rago, C., Cheong, I., Pagliarini, R., Angenendt, P., Rajagopalan, H., Schmidt, K., Willson, J. K. V., Markowitz, S., Zhou, S., et al. (2009) · Science · doi:10.1126/science.1174229 · Cited by 914
Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc
Osthus, R. C., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., Xu, Y., Wonsey, D. R., Lee, L. A., & Dang, C. V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000023200 · Cited by 876
Mutational landscape and clonal architecture in grade II and III gliomas
Suzuki, H., Aoki, K., Chiba, K., Sato, Y., Shiozawa, Y., Shiraishi, Y., Shimamura, T., Niida, A., Motomura, K., Ohka, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3273 · Cited by 831
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A.-J., Perry, S. R., Tonon, G., Chu, G. C., Ding, Z., et al. (2008) · Nature · doi:10.1038/nature07443 · Cited by 767
The NAD metabolome — a key determinant of cancer cell biology
Chiarugi, A., Dölle, C., Felici, R., & Ziegler, M. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3340 · Cited by 660
CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
Chipumuro, E., Marco, E., Christensen, C. L., Kwiatkowski, N. P., Zhang, T., Hatheway, C. M., Abraham, B. J., Sharma, B., Yeung, C. M., Altabef, A. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.024 · Cited by 631
Hasmann, M., & Schemainda, I. (2003) · PubMed · Cited by 617
Amino Acid Analysis by Capillary Electrophoresis Electrospray Ionization Mass Spectrometry
Soga, T., & Heiger, D. N. (2000) · Analytical Chemistry · doi:10.1021/ac990976y · Cited by 520
Soga, T., Ueno, Y., Naraoka, H., Ohashi, Y., Tomita, M., & Nishioka, T. (2002) · Analytical Chemistry · doi:10.1021/ac020064n · Cited by 473
Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion
Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433
Self-citationc-Myc Is Required for Maintenance of Glioma Cancer Stem Cells
Wang, J., Wang, H., Li, Z., Wu, Q., Lathia, J. D., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003769 · Cited by 430
Kim, H., Zheng, S., Amini, S. S., Virk, S. M., Mikkelsen, T., Brat, D. J., Grimsby, J., Sougnez, C., Muller, F., Hu, J., et al. (2015) · Genome Research · doi:10.1101/gr.180612.114 · Cited by 411
Masui, K., Tanaka, K., Akhavan, D., Babic, I., Gini, B., Matsutani, T., Iwanami, A., Liu, F., Villa, G. R., Gu, Y., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.09.013 · Cited by 407
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
Murga, M., Campaner, S., Lopez-Contreras, A. J., Toledo, L. I., Soria, R., Montaña, M. F., D'Artista, L., Schleker, T., Guerra, C., Garcia, E., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2189 · Cited by 381
Wakimoto, H., Kesari, S., Farrell, C. J., Curry, W. T., Zaupa, C., Aghi, M. K., Kuroda, T., Stemmer-Rachamimov, A. O., Shah, K., Liu, T., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3886 · Cited by 361
Self-citationIntegrated genomic characterization of IDH1-mutant glioma malignant progression
Bai, H., Harmancı, A. S., Erson-Omay, Z., Li, J., Coşkun, S., Simon, M., Krischek, B., Özduman, K., Omay, S. B., Sorensen, E. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3457 · Cited by 328
Spatiotemporal Evolution of the Primary Glioblastoma Genome
Kim, J., Lee, I., Cho, H. J., Park, C., Jung, Y.-S., Kim, Y., Nam, S. H., Kim, B. S., Johnson, M. D., Kong, D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.013 · Cited by 323
A unique glucose-dependent apoptotic pathway induced by c-Myc
Shim, H., Chun, Y. S., Lewis, B. C., & Dang, C. V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1511 · Cited by 286
Menssen, A., Hydbring, P., Kapelle, K., Vervoorts, J., Diebold, J., Lüscher, B., Larsson, L., & Hermeking, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105304109 · Cited by 275
Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells
Wakimoto, H., Mohapatra, G., Kanai, R., Curry, W. T., Yip, S. S. F., Nitta, M., Patel, A. P., Barnard, Z. R., Stemmer-Rachamimov, A. O., Louis, D. N., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor195 · Cited by 245
Self-citationWatson, M., Roulston, A., Bélec, L., Billot, X., Marcellus, R., Bédard, D., Bernier, C., Branchaud, S., Chan, H., Dairi, K., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00112-09 · Cited by 229
Hui, A. B., Lo, K. W., Yin, X.-L., Poon, W. S., & Ng, H. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780280 · Cited by 212
Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis
Annibali, D., Whitfield, J. R., Favuzzi, E., Jauset, T., Serrano, E., Cuartas, I., Redondo-Campos, S., Folch, G., Gonzàlez-Juncà, A., Sodir, N. M., et al. (2014) · Nature Communications · doi:10.1038/ncomms5632 · Cited by 200
Wakimoto, H., Tanaka, S., Curry, W. T., Loebel, F., Zhao, D., Tateishi, K., Chen, J., Klofas, L. K., Lelic, N., Kim, J. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3052 · Cited by 190
Self-citationTan, B., Young, D. A., Lu, Z.-H., Wang, T., Meier, T. I., Shepard, R. L., Roth, K. D. W., Zhai, Y. W., Huss, K., Kuo, M., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394510 · Cited by 181
Medicinal Chemistry of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors
Galli, U., Travelli, C., Massarotti, A., Fakhfouri, G., Rahimian, R., Tron, G. C., & Genazzani, A. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4001049 · Cited by 157
Hodgson, J., Yeh, R.-F., Ray, A., Wang, N. J., Smirnov, I. V., Yu, M., Hariono, S., Silber, J., Feiler, H. S., Gray, J. W., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-113 · Cited by 149
Luan, W., Wang, Y., Chen, X., Shi, Y., Wang, J., Zhang, J., Qian, J., Li, R., Tao, T., Wei, W., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3514 · Cited by 146
CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo.
Hjarnaa, P. V., Jonsson, E. W., Latini, S., Dhar, S., Larsson, R., Bramm, E., Skov, T., & Binderup, L. (1999) · PubMed · Cited by 115
Therapeutic Targeting of Myc-Reprogrammed Cancer Cell MetabolismPreprint
Dang, C. V. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.011296 · Cited by 104
Wosikowski, K., Mattern, K., Schemainda, I., Hasmann, M., Rattel, B., & Löser, R. (2002) · PubMed · Cited by 89
Shames, D. S., Elkins, K., Walter, K., Holcomb, T., Du, P., Mohl, D. A., Xiao, Y., Pham, T., Haverty, P. M., Liederer, B. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1186 · Cited by 85
Tolstikov, V., Nikolayev, A., Dong, S., Zhao, G., & Kuo, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114019 · Cited by 84
Myc increases self-renewal in neural progenitor cells through Miz-1
Kerosuo, L., Piltti, K. M., Fox, H., Angers‐Loustau, A., Häyry, V., Eilers, M., Sariola, H. V., & Wartiovaara, K. (2008) · Journal of Cell Science · doi:10.1242/jcs.024802 · Cited by 66
Zhang, L., Liu, L., Qie, L.-L., Ling, K.-N., Xu, L.-H., Wang, F., Fang, S., Lu, Y., Hu, H., Wei, E.-Q., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.11.017 · Cited by 39
Flagged first, then by citations
2 of the 50 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Hjarnaa, 1999, CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity invitro and invivo, Cancer Res, 59, 5751
Cited by
Sorted by citations
Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
The role of m6A RNA methylation in cancer metabolism
An, Y., & Duan, H. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01500-4 · Cited by 904
NAD+ metabolism, stemness, the immune response, and cancer
Navas, L. E., & Carnero, A. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00354-w · Cited by 551
LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer
Wang, Y., Lu, J.-H., Wu, Q.-N., Jin, Y., Wang, D.-S., Chen, Y.-X., Liu, J., Luo, X.-J., Meng, Q., Pu, H.-Y., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1105-0 · Cited by 507
Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance
Liu, Y., Liang, G., Xu, H., Dong, W., Dong, Z., Qiu, Z., Zhang, Z., Li, F., Huang, Y., Li, Y., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.04.001 · Cited by 370
Altered cellular metabolism in gliomas — an emerging landscape of actionable co-dependency targets
Bi, J., Chowdhry, S., Wu, S., Zhang, W., Masui, K., & Mischel, P. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0226-5 · Cited by 352
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A. R., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 347
The Glycolytic Switch in Tumors: How Many Players Are Involved?
Yu, L., Chen, X., Sun, X., Wang, L., & Chen, S. (2017) · Journal of Cancer · doi:10.7150/jca.21125 · Cited by 240
Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance
Zhou, W., & Wahl, D. R. (2019) · Cancers · doi:10.3390/cancers11091231 · Cited by 150
NAD+ salvage pathway in cancer metabolism and therapy
Kennedy, B. E., Sharif, T., Martell, E., Dai, C., Kim, Y., Lee, P. W. K., & Gujar, S. A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.10.027 · Cited by 149
Nicotinamide metabolism regulates glioblastoma stem cell maintenance
Jung, J., Kim, L. J. Y., Wang, X., Wu, Q., Sanvoranart, T., Hubert, C. G., Prager, B. C., Wallace, L. C., Jin, X., Mack, S. C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90019 · Cited by 145
Wei, J., Huang, K., Hu, M., Chen, Z., Bai, Y., Lin, S., & Du, H. (2020) · Cancers · doi:10.3390/cancers12071788 · Cited by 143
Gujar, A. D., Le, S. B., Mao, D. D., Dadey, D. Y. A., Turski, A., Sasaki, Y., Aum, D. J., Luo, J. R., Dahiya, S. M., Yuan, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610921114 · Cited by 134
Ning, J.-F., Stanciu, M., Humphrey, M. R., Gorham, J., Wakimoto, H., Nishihara, R., Lees, J. A., Zou, L., Martuza, R. L., Wakimoto, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10993-5 · Cited by 120
Self-citationBeyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy
Heske, C. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01514 · Cited by 113
Zhang, F., Liu, H., Duan, M., Wang, G., Zhang, Z., Wang, Y., Qian, Y., Yang, Z., & Jiang, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01304-5 · Cited by 111
The role of Wnt signaling pathway in tumor metabolic reprogramming
Mo, Y., Wang, Y., Zhang, L., Yang, L., Zhou, M., Li, X., Li, Y., Li, G., Zeng, Z., Xiong, W., et al. (2019) · Journal of Cancer · doi:10.7150/jca.31166 · Cited by 106
Targeting Glutamine Addiction in Gliomas
Obara‐Michlewska, M., & Szeliga, M. (2020) · Cancers · doi:10.3390/cancers12020310 · Cited by 106
Pinkham, K., Park, D. J., Hashemiaghdam, A., Kirov, A. B., Adam, I., Rosiak, K., da Hora, C. C., Teng, J., Cheah, P.-S., de Carvalho, L. A., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.02.012 · Cited by 104
Yang, R., Li, X., Wu, Y., Zhang, G., Liu, X., Li, Y., Bao, Y., Yang, W., & Cui, H. (2020) · Oncogene · doi:10.1038/s41388-020-1199-2 · Cited by 101
MYC and therapy resistance in cancer: risks and opportunities
Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 104
Tateishi, K., Higuchi, F., Miller, J. J., Koerner, M. V. A., Lelic, N., Shankar, G. M., Tanaka, S., Fisher, D. E., Batchelor, T. T., Iafrate, A. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2263 · Cited by 100
Self-citationNagashima, H., Lee, C. K., Tateishi, K., Higuchi, F., Subramanian, M. P., Rafferty, S., Melamed, L., Miller, J. J., Wakimoto, H., & Cahill, D. P. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0226 · Cited by 90
Self-citationZhao, N., Wang, F., Ahmed, S., Liu, K., Zhang, C., Cathcart, S. J., DiMaio, D. J., Punsoni, M., Guan, B., Zhou, P., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.616625 · Cited by 81
Glioblastoma’s Next Top Model: Novel Culture Systems for Brain Cancer Radiotherapy Research
Caragher, S. P., Chalmers, A. J., & Gomez-Roman, N. (2019) · Cancers · doi:10.3390/cancers11010044 · Cited by 80
Yang, R., Wang, M., Zhang, G., Li, Y., Wang, L., & Cui, H. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03719-3 · Cited by 72
The Role of Hypoxia and SRC Tyrosine Kinase in Glioblastoma Invasiveness and Radioresistance
Torrisi, F., Vicario, N., Spitale, F. M., Cammarata, F. P., Minafra, L., Salvatorelli, L., Russo, G. I., Cuttone, G., Valable, S., Gulino, R., et al. (2020) · Cancers · doi:10.3390/cancers12102860 · Cited by 59
Glioblastoma Metabolism: Insights and Therapeutic Strategies
Bernhard, C., Reita, D., Martin, S., Entz‐Werlé, N., & Dontenwill, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119137 · Cited by 66
Salmina, A. B., Kharitonova, E. V., Gorina, Y. V., Тепляшина, Е. А., Malinovskaya, N. A., Хилажева, Е. Д., Mosiagina, A. I., Morgun, A. V., Shuvaev, А. N., Salmin, V. V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094661 · Cited by 63
Li, M., Kirtane, A. R., Kiyokawa, J., Nagashima, H., Lopes, A., Tirmizi, Z. A., Lee, C. K., Traverso, G., Cahill, D. P., & Wakimoto, H. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1094 · Cited by 60
Self-citationEPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells
Sagar, V., Vatapalli, R. J., Lysy, B., Pamarthy, S., Anker, J. F., Rodríguez, Y., Han, H., Unno, K., Stadler, W. M., Catàlona, W. J., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2042-y · Cited by 54
Conde, M., Michen, S., Wiedemuth, R., Klink, B., Schröck, E., Schackert, G., & Temme, A. (2017) · BMC Cancer · doi:10.1186/s12885-017-3932-y · Cited by 53
Construction of Potential Glioblastoma Multiforme-Related miRNA-mRNA Regulatory Network
Lou, W., Ding, B., Xu, L., & Fan, W. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00066 · Cited by 52
Shen, H. M., Cook, K. M., Gee, H. E., & Hau, E. K. C. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01639-2 · Cited by 52
Cancer Stem Cell-Associated Pathways in the Metabolic Reprogramming of Breast Cancer
El‐Sahli, S., & Wang, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239125 · Cited by 52
Bian, E., Chen, X., Cheng, L., Cheng, M., Chen, Z., Yue, X., Zhang, Z., Chen, J., Sun, L., Huang, K., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02129-9 · Cited by 51
Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells
Alharris, E. S., Singh, N. P., Nagarkatti, P. S., & Nagarkatti, M. (2019) · Oncotarget · doi:10.18632/oncotarget.26534 · Cited by 50
SRC Kinase in Glioblastoma: News from an Old Acquaintance
Cirotti, C., Contadini, C., & Barilà, D. (2020) · Cancers · doi:10.3390/cancers12061558 · Cited by 49
BRD4: New hope in the battle against glioblastoma
Duan, W., Yu, M., & Chen, J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106767 · Cited by 49
Super-enhancers complexes zoom in transcription in cancer
Wang, M., Chen, Q., Wang, S., Xie, H., Liu, J., Huang, R., Xiang, Y., Jiang, Y., Tian, D., & Bian, E. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02763-5 · Cited by 51
Tateishi, K., Nakamura, T., Juratli, T. A., Williams, E. A., Matsushita, Y., Miyake, S., Nishi, M., Miller, J. J., Tummala, S. S., Fink, A. L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4144 · Cited by 48
Self-citationWang, R., Zhuang, J., Zhang, Q., Wu, W., Yu, X., Zhang, H., & Xie, Z. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00689-6 · Cited by 52
Higuchi, F., Fink, A. L., Kiyokawa, J., Miller, J. J., Koerner, M. V. A., Cahill, D. P., & Wakimoto, H. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0177 · Cited by 46
Self-citationcircPTPN4 regulates myogenesis via the miR-499-3p/NAMPT axis
Cai, B., Ma, M., Zhou, Z., Kong, S., Zhang, J., Zhang, X., & Nie, Q. (2022) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-021-00664-1 · Cited by 47
Lan, Y., Lou, J., Hu, J., Yu, Z., Lyu, W., & Zhang, B. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0164 · Cited by 46
Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis
Richardson, T. E., Snuderl, M., Serrano, J., Karajannis, M. A., Heguy, A., Oliver, D., Raisanen, J. M., Maher, E. A., Pan, E., Barnett, S. L., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2431-y · Cited by 45
Zhang, Y., Zhang, B., Lv, C., Zhang, N., Xing, K., Wang, Z., Lv, R., Yu, M., Xu, C., & Wang, Y. (2023) · Theranostics · doi:10.7150/thno.81407 · Cited by 45
Mair, R. J., Wright, A. J., R�os, S., Hu, D., Booth, T., Kreis, F., Rao, J. U., Watts, C., & Brindle, K. M. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0759 · Cited by 44
Lucena-Cacace, A., Umeda, M., Navas, L. E., & Carnero, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00292 · Cited by 42
Takahashi, H., Kawabata‐Iwakawa, R., Ida, S., Mito, I., Tada, H., & Chikamatsu, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-97292-6 · Cited by 43
The role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities
Cordani, M., Michetti, F., Zarrabi, A., Zarepour, A., Rumio, C., Strippoli, R., & Marcucci, F. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101076 · Cited by 40
Tang, H., Wang, L., Wang, T., Yang, J., Zheng, S., Tong, J., Jiang, S., Zhang, X., & Zhang, K. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115607 · Cited by 37
Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells
Trejo‐Solís, C., Castillo‐Rodríguez, R. A., Serrano-García, N., Silva‐Adaya, D., Vargas-Cruz, S., Chávez-Cortéz, E. G., Gallardo‐Pérez, J. C., Zavala-Vega, S., Cruz-Salgado, A., & Magaña-Maldonado, R. (2024) · Metabolites · doi:10.3390/metabo14050249 · Cited by 41
Identification of a novel NAMPT inhibitor by CRISPR/Cas9 chemogenomic profiling in mammalian cells
Estoppey, D., Hewett, J. W., Guy, C. T., Harrington, E. M., Thomas, J. R., Schirle, M., Cuttat, R., Waldt, A., Gerrits, B., Yang, Z., et al. (2017) · Scientific Reports · doi:10.1038/srep42728 · Cited by 37
Chen, C., Shi, Y., Li, Y., He, Z., Zhou, K., Zhang, X., Yang, K., Wu, J.-R., Kung, H., Ping, Y., et al. (2017) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2017.05.007 · Cited by 38
Zhang, C., Wang, M., Ji, F., Peng, Y., Wang, B., Zhao, J., Wu, J., & Zhao, H. (2021) · BioMed Research International · doi:10.1155/2021/8872977 · Cited by 37
Haltom, A. R., Hassen, W. E., Hensel, J., Kim, J., Sugimoto, H., Li, B., McAndrews, K. M., Conner, M. R., Kirtley, M. L., Luo, X., et al. (2022) · Extracellular Vesicle · doi:10.1016/j.vesic.2022.100014 · Cited by 36
Raninga, P. V., He, Y., Datta, K. K., Lu, X. M., Maheshwari, U. R., Venkat, P., Mayoh, C., Gowda, H., Kalimutho, M., Hooper, J. D., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.12.011 · Cited by 36
Li, M., Kirtane, A. R., Kiyokawa, J., Nagashima, H., Lopes, A., Tirmizi, Z. A., Lee, C. K., Traverso, G., Cahill, D. P., & Wakimoto, H. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0525 · Cited by 36
Self-citationMicroRNA Regulation of Glycolytic Metabolism in Glioblastoma
Alfardus, H., McIntyre, A., & Smith, S. J. (2017) · BioMed Research International · doi:10.1155/2017/9157370 · Cited by 33
Yin, Y., Sun, M., Zhan, X., Wu, C., Geng, P., Sun, X., Wu, Y., Zhang, S., Qin, J., Zhuang, Z., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1082-6 · Cited by 34
Therapeutic Drug-Induced Metabolic Reprogramming in Glioblastoma
Nguyen, T. T. T., Shang, E., Westhoff, M., Karpel‐Massler, G., & Siegelin, M. D. (2022) · Cells · doi:10.3390/cells11192956 · Cited by 32
Prodrug nanoparticles potentiate tumor chemo-immunometabolic therapy by disturbing oxidative stress
Zhao, H., Li, Y., Shi, H., Niu, M., Li, D., Zhang, Z., Feng, Q., Zhang, Y., & Wang, L. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.011 · Cited by 33
Yang, R., Zhang, G., Meng, Z., Wang, L., Li, Y., Li, H., Yan, S., Wei, X., Wang, S., & Cui, H. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae222 · Cited by 35
TGF-β links glycolysis and immunosuppression in glioblastoma.
Gong, L., Li, J., Xu, D., Wang, J., & Zou, J. (2021) · PubMed · doi:10.14670/hh-18-366 · Cited by 29
Temozolomide Treatment Increases Fatty Acid Uptake in Glioblastoma Stem Cells
Caragher, S. P., Miska, J. M., Shireman, J. M., Park, C. H., Muroski, M. E., Lesniak, M. S., & Ahmed, A. U. (2020) · Cancers · doi:10.3390/cancers12113126 · Cited by 27
Transcription factors in glioblastoma – Molecular pathogenesis and clinical implications
Papavassiliou, K. A., & Papavassiliou, A. G. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188667 · Cited by 27
Dong, Z., Zhong, X., Lei, Q., Chen, F., & Cui, H. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.04.009 · Cited by 26
Li, Z., Shao, S., Ren, X., Sun, J., Guo, Z., Wang, S., Song, M. M., Chang, C. A., & Xue, M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08338 · Cited by 25
Yuan, Y., Wang, L., Zhao, X., Wang, J., Zhang, M., Ma, Q., Wei, S., Yan, Z., Cheng, Y., Chen, X., et al. (2022) · 癌症：英文版 · doi:10.1002/cac2.12334 · Cited by 25
Li, X., Moreira, D. C., Bag, A. K., Qaddoumi, I. A., Acharya, S., & Chiang, J. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac241 · Cited by 27
Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression
Xie, Y., Ning, S., & Hu, J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04061-7 · Cited by 25
The CD73 immune checkpoint promotes tumor cell metabolic fitness
Allard, D., Cousineau, I., Ma, E. H., Allard, B., Barèche, Y., Fleury, H., & Stagg, J. (2023) · eLife · doi:10.7554/elife.84508 · Cited by 26
Cencioni, C., Scagnoli, F., Spallotta, F., Nasi, S., & Illi, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044217 · Cited by 28
Aspirin induces immunogenic cell death and enhances cancer immunotherapy in colorectal cancer
Lei, J., Zhou, Z., Fang, J., Sun, Z., He, M., He, B., Chen, Q., Paek, C., Chen, P., Zhou, J., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110350 · Cited by 23
Wang, H., Xu, P., Yin, K., & Wang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1521196 · Cited by 22
Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC‐driven lymphoma
Donati, G., Nicoli, P., Verrecchia, A., Vallelonga, V., Croci, O., Rodighiero, S., Audano, M., Cassina, L., Ghsein, A., Binelli, G., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202216910 · Cited by 21
Glioma Stem-Like Cells and Metabolism: Potential for Novel Therapeutic Strategies
Harland, A. J., Liu, X., Ghirardello, M., Galán, M. C., Perks, C. M., & Kurian, K. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.743814 · Cited by 21
Metabolic reprogramming directed by super-enhancers in tumors: An emerging landscape
Zhou, Z., Li, J., Ousmane, D., Peng, L., Yuan, X., & Wang, J. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.02.003 · Cited by 22
Xue, Y., Fu, Y., Zhao, F., Gui, G., Li, Y., Rivero-Hinojosa, S., Liu, G., Li, Y.-Q., Xia, S., Eberhart, C. G., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0603 · Cited by 20
Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance
Bailleul, J., & Vlashi, E. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0088 · Cited by 22
Sradhanjali, S., Rout, P., Tripathy, D., Kaliki, S., Rath, S., Modak, R., Mittal, R., Chowdary, T. K., & Reddy, M. M. (2021) · Cancers · doi:10.3390/cancers13205248 · Cited by 19
Metabolism and signaling crosstalk in glioblastoma progression and therapy resistance
Zarzuela, L., Durán, R. V., & Tomé, M. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13571 · Cited by 19
Wang, S., Guo, X., Lv, W., Li, Y., Zhang, L., Dong, C., Zhang, J., & Cheng, G. (2020) · Cancer Management and Research · doi:10.2147/cmar.s227496 · Cited by 19
Proline Metabolism in Malignant Gliomas: A Systematic Literature Review
Sawicka, M. M., Sawicki, K., Łysoń, T., Polityńska, B., & Miltyk, W. (2022) · Cancers · doi:10.3390/cancers14082030 · Cited by 19
Savvidou, I., Khong, T. T., Whish, S., Carmichael, I., Sepehrizadeh, T., Mithraprabhu, S., Horrigan, S. K., de Veer, M., & Spencer, A. G. (2022) · Cancers · doi:10.3390/cancers14030840 · Cited by 16
Yuan, J., Wang, S.-M., & Guo, L. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13294 · Cited by 16
2-Deoxyglucose, an Inhibitor of Glycolysis, Enhances the Oncolytic Effect of Coxsackievirus
Vorobyev, P. O., Кочетков, Д. В., Chumakov, P. M., Zakirova, N. F., Zotova-Nefedorova, S., Василенко, К. В., Alekseeva, O. N., Kochetkov, S. N., Bartosch, B., Lipatova, A. V., et al. (2022) · Cancers · doi:10.3390/cancers14225611 · Cited by 16
Cell to cell communication mediates glioblastoma progression in Drosophila
Portela, M., Mitchell, T., & Casas‐Tintó, S. (2020) · Biology Open · doi:10.1242/bio.053405 · Cited by 15
Tumor Microenvironment Metabolism‐Modulating Nanomedicines for Enhancing Anti‐Tumor Immunity
Chen, J., Fei, S., Cao, Z., Liu, X., Ji, W., Chen, H., Niu, Y., & Yang, Z. (2025) · Small · doi:10.1002/smll.202509685 · Cited by 15
The Role of NAD+, SIRTs Interactions in Stimulating and Counteracting Carcinogenesis
Podyacheva, E., & Toropova, Y. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097925 · Cited by 14
McKay-Corkum, G. B., Collins, V. J., Yeung, C. L., Ito, T., Issaq, S. H., Holland, D. O., Vulikh, K., Zhang, Y., Lee, U., Lei, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0200 · Cited by 15
Yeung, C. L. S., Ng, T. H., Lai, C. J., Xue, T., Mao, X., Tey, S. K., Lo, R. C., Sin, C., Ng, K. M., Wong, D. K.-H., et al. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70071 · Cited by 12
Jarabo, P., de Pablo, C., González-Blanco, A., & Casas‐Tintó, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042043 · Cited by 12
The identification of key genes and pathways in glioblastoma by bioinformatics analysis
Farsi, Z., & Fard, N. A. (2023) · Molecular & Cellular Oncology · doi:10.1080/23723556.2023.2246657 · Cited by 12
Sviderskiy, V. O., Vasudevaraja, V., Dubois, L. G., Stafford, J. M., Liu, E. K., Serrano, J., Possemato, R., & Snuderl, M. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-01961-w · Cited by 12
The Role of Network Science in Glioblastoma
Lopes, M. B., Martins, E. P., Vinga, S., & Costa, B. M. (2021) · Cancers · doi:10.3390/cancers13051045 · Cited by 15
Helweg, L. P., Storm, J., Witte, K. E., Schulten, W., Wrachtrup, L., Janotte, T., Kitke, A., Greiner, J. F. W., Knabbe, C., Kaltschmidt, B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112919 · Cited by 12
Stuart, S. F., Bezawork‐Geleta, A., Areeb, Z., Gomez, J., Tsui, V., Zulkifli, A., Paradiso, L., Jones, J., Nguyen, H. P. T., Putoczki, T. L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043356 · Cited by 12
Li, R., & Yang, W. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.05.109 · Cited by 12
Metadata
- Authors
- Tateishi, K., Iafrate, A. J., Ho, Q., Curry, W. T., Batchelor, T. T., Flaherty, K. T., Onozato, M. L., Lelic, N., Sundaram, S., Cahill, D. P., Chi, A. S., & Wakimoto, H.
- Affiliations
- Harvard University (US)
- NYU Langone Health (US)
- Corresponding author
- Cahill, Daniel P.
- Chi, Andrew S.
- Wakimoto, Hiroaki
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2016-08-31
- Volume
- 22
- Issue
- 17
- Pages
- 4452-4465
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC5010492
- OpenAlex
- W2341529963
- Cited by
- 160
- References
- 50
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 11 · 2023: 21 · 2022: 22 · 2021: 28 · 2020: 21 · 2019: 15 · 2018: 3 · 2017: 10 · 2016: 3
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Japan Society for the Promotion of Science (16K10765)
- National Cancer Institute (K24CA125440, P50CA165962)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- glioblastoma, c-Myc, MYCN amplification, glycolysis, NAMPT inhibitors, cancer metabolism, metabolic targeting therapy, cancer stem cells, glucose flux, apoptosis, orthotopic xenograft
- MeSH terms
- Animals, Antineoplastic Agents, Disease Models, Animal, Gene Amplification, Glioblastoma, Glucose, Glycolysis, Humans, NAD, Proto-Oncogene Proteins c-myc, Apoptosis, Xenograft Model Antitumor Assays, RNA Interference, RNA, Small Interfering, Cell Line, Tumor, Mice, Nicotinamide Phosphoribosyltransferase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
